Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study.

Sun JK, Maturi RK, Boyer DS, Wells JA, Gonzalez VH, Tansley R, Hernandez H, Maetzel A, Feener EP, Aiello LP.

Ophthalmol Retina. 2019 Dec;3(12):1107-1109. doi: 10.1016/j.oret.2019.07.006. Epub 2019 Jul 26. No abstract available.

PMID:
31810575
2.

Natural history of diabetic macular edema and factors predicting outcomes in sham-treated patients (MEAD study).

Yoon YH, Boyer DS, Maturi RK, Bandello F, Belfort R Jr, Augustin AJ, Li XY, Bai Z, Hashad Y; Ozurdex MEAD Study Group.

Graefes Arch Clin Exp Ophthalmol. 2019 Dec;257(12):2639-2653. doi: 10.1007/s00417-019-04464-2. Epub 2019 Oct 25.

PMID:
31654188
3.

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.

Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, Wykoff CC, Singerman LJ, Abraham P, Grassmann F, Nuernberg P, Weber BHF, Deschatelets P, Kim RY, Chung CY, Ribeiro RM, Hamdani M, Rosenfeld PJ, Boyer DS, Slakter JS, Francois CG.

Ophthalmology. 2019 Jul 16. pii: S0161-6420(18)33132-4. doi: 10.1016/j.ophtha.2019.07.011. [Epub ahead of print]

4.

Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.

Ehlers JP, Uchida A, Hu M, Figueiredo N, Kaiser PK, Heier JS, Brown DM, Boyer DS, Do DV, Gibson A, Saroj N, Srivastava SK.

Ophthalmol Retina. 2019 Dec;3(12):1056-1066. doi: 10.1016/j.oret.2019.06.010. Epub 2019 Jul 6.

PMID:
31473172
5.

Outcomes of Diabetic Macular Edema Eyes with Limited Early Response in the VISTA and VIVID Studies.

Pieramici D, Singh RP, Gibson A, Saroj N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Soo Y, Zhu X, Boyer DS.

Ophthalmol Retina. 2018 Jun;2(6):558-566. doi: 10.1016/j.oret.2017.10.014. Epub 2017 Dec 19.

PMID:
31047609
6.

Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies.

Mitchell P, McAllister I, Larsen M, Staurenghi G, Korobelnik JF, Boyer DS, Do DV, Brown DM, Katz TA, Berliner A, Vitti R, Zeitz O, Metzig C, Lu C, Holz FG.

Ophthalmol Retina. 2018 Oct;2(10):988-996. doi: 10.1016/j.oret.2018.02.011. Epub 2018 Mar 31.

PMID:
31047501
7.

Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study.

Campochiaro PA, Wykoff CC, Brown DM, Boyer DS, Barakat M, Taraborelli D, Noronha G; Tanzanite Study Group.

Ophthalmol Retina. 2018 Apr;2(4):320-328. doi: 10.1016/j.oret.2017.07.013. Epub 2017 Sep 29.

PMID:
31047241
8.

Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.

Khanani AM, Duker JS, Heier JS, Kaiser PK, Joondeph BC, Kozma P, Rosberger DF, MacCumber M, Boyer DS, Pieramici DJ.

Ophthalmol Retina. 2019 Jan;3(1):32-41. doi: 10.1016/j.oret.2018.07.011. Epub 2018 Jul 25.

PMID:
30935657
9.

Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence.

Chakravarthy U, Bezlyak V, Sagkriotis A, Griner R, Skelly A, Boyer DS, Milnes F.

Ophthalmol Retina. 2019 Jan;3(1):8-15.e1. doi: 10.1016/j.oret.2018.09.001. Epub 2018 Sep 15.

PMID:
30929819
10.

Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes.

Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group.

Am J Ophthalmol. 2019 Jun;202:91-99. doi: 10.1016/j.ajo.2019.02.005. Epub 2019 Feb 14.

PMID:
30771333
11.

Outcomes of small-gauge vitreoretinal surgery without scleral-depressed shaving of the vitreous base in the era of wide-angle viewing systems.

Tabandeh H, London NJS, Boyer DS, Flynn HW Jr.

Br J Ophthalmol. 2019 Dec;103(12):1765-1768. doi: 10.1136/bjophthalmol-2018-313626. Epub 2019 Feb 15.

PMID:
30770355
12.

Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials.

Khurana RN, Rahimy E, Joseph WA, Saroj N, Gibson A, Vitti R, Berliner AJ, Chu K, Cheng Y, Boyer DS.

Am J Ophthalmol. 2019 Apr;200:161-168. doi: 10.1016/j.ajo.2019.01.005. Epub 2019 Jan 19.

PMID:
30664844
13.

Recent advances in understanding and managing retinal vein occlusions.

Esmaili DD, Boyer DS.

F1000Res. 2018 Apr 16;7:467. doi: 10.12688/f1000research.12886.1. eCollection 2018. Review.

14.

Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema.

Payne JF, Clark WL, Bruce BB, Wykoff CC, Brown DM, Menke BM, Iverson SM, Allen KF, Boyer DS; Treat & Extend Protocol in Patients with Diabetic Macular Edema Study Group.

Ophthalmology. 2018 Aug;125(8):1304-1306. doi: 10.1016/j.ophtha.2018.03.046. Epub 2018 May 3. No abstract available.

PMID:
29729809
15.

Effects of Repeated Intravitreal Aflibercept Injection on the Corneal Endothelium in Patients With Age-Related Macular Degeneration: Outcomes From the RE-VIEW Study.

Lass JH, Benetz BA, Menegay HJ, Tsipis CP, Cook JC, Boyer DS, Singer M, Erickson K, Saroj N, Vitti R, Chu KW, Moini H, Soo Y, Cheng Y.

Cornea. 2018 May;37(5):596-601. doi: 10.1097/ICO.0000000000001535.

PMID:
29384810
16.

Integrated results from the COPERNICUS and GALILEO studies.

Pielen A, Clark WL, Boyer DS, Ogura Y, Holz FG, Korobelnik JF, Stemper B, Asmus F, Rittenhouse KD, Ahlers C, Vitti R, Saroj N, Zeitz O, Haller JA.

Clin Ophthalmol. 2017 Aug 23;11:1533-1540. doi: 10.2147/OPTH.S140665. eCollection 2017.

17.

Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease.

Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ, Kile SJ, Blanco A, Fuchs DT, Ashfaq A, Frautschy S, Cole GM, Miller CA, Hinton DR, Verdooner SR, Black KL, Koronyo-Hamaoui M.

JCI Insight. 2017 Aug 17;2(16). pii: 93621. doi: 10.1172/jci.insight.93621. eCollection 2017 Aug 17.

18.

Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.

Wykoff CC, Ou WC, Khurana RN, Brown DM, Lloyd Clark W, Boyer DS; ENDURANCE Study Group.

Br J Ophthalmol. 2018 May;102(5):631-636. doi: 10.1136/bjophthalmol-2017-310941. Epub 2017 Aug 16.

PMID:
28814412
19.

Postreceptor Neuronal Loss in Intermediate Age-related Macular Degeneration.

Borrelli E, Abdelfattah NS, Uji A, Nittala MG, Boyer DS, Sadda SR.

Am J Ophthalmol. 2017 Sep;181:1-11. doi: 10.1016/j.ajo.2017.06.005. Epub 2017 Jun 15.

PMID:
28624323
20.

Reply.

Wykoff CC, Le RT, Khurana RN, Brown DM, Ou WC, Wang R, Clark WL, Boyer DS; ENDURANCE Study Group.

Am J Ophthalmol. 2017 May;177:236-237. doi: 10.1016/j.ajo.2017.02.024. Epub 2017 Mar 14. No abstract available.

PMID:
28302270
21.

Variability of Retinal Thickness Measurements in Tilted or Stretched Optical Coherence Tomography Images.

Uji A, Abdelfattah NS, Boyer DS, Balasubramanian S, Lei J, Sadda SR.

Transl Vis Sci Technol. 2017 Mar 1;6(2):1. doi: 10.1167/tvst.6.2.1. eCollection 2017 Mar.

22.

Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema.

Clark WL, Boyer DS, Kaiser PK.

JAMA Ophthalmol. 2017 Mar 1;135(3):291. doi: 10.1001/jamaophthalmol.2016.5676. No abstract available.

PMID:
28152149
23.

The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good.

Ho AC, Albini TA, Brown DM, Boyer DS, Regillo CD, Heier JS.

JAMA Ophthalmol. 2017 Mar 1;135(3):268-273. doi: 10.1001/jamaophthalmol.2016.5314. Review.

PMID:
28114653
24.

THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET.

Boyer DS, Schmidt-Erfurth U, van Lookeren Campagne M, Henry EC, Brittain C.

Retina. 2017 May;37(5):819-835. doi: 10.1097/IAE.0000000000001392. Review.

25.

Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes.

Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group.

Ophthalmology. 2017 Jan;124(1):74-81. doi: 10.1016/j.ophtha.2016.09.021. Epub 2016 Nov 8.

PMID:
27836430
26.

Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.

Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, Boyer DS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Vitti R, Berliner AJ, Zeitz O, Metzig C, Holz FG.

Ophthalmology. 2016 Nov;123(11):2376-2385. doi: 10.1016/j.ophtha.2016.07.032. Epub 2016 Sep 17.

PMID:
27651226
27.

Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.

Wykoff CC, Le RT, Khurana RN, Brown DM, Ou WC, Wang R, Clark WL, Boyer DS; ENDURANCE Study Group.

Am J Ophthalmol. 2017 Jan;173:56-63. doi: 10.1016/j.ajo.2016.09.029. Epub 2016 Oct 1.

28.

Reply.

Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA.

Ophthalmology. 2016 Oct;123(10):e60-1. doi: 10.1016/j.ophtha.2016.03.020. No abstract available.

PMID:
27664917
29.

PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.

Abdelfattah NS, Zhang H, Boyer DS, Sadda SR.

Retina. 2016 Oct;36(10):1843-50. doi: 10.1097/IAE.0000000000001059.

PMID:
27135213
30.

Increased expression of ApoE and protection from amyloid-beta toxicity in transmitochondrial cybrids with haplogroup K mtDNA.

Thaker K, Chwa M, Atilano SR, Coskun P, Cáceres-Del-Carpio J, Udar N, Boyer DS, Jazwinski SM, Miceli MV, Nesburn AB, Kuppermann BD, Kenney MC.

Neurobiol Dis. 2016 Sep;93:64-77. doi: 10.1016/j.nbd.2016.04.005. Epub 2016 Apr 22.

31.

Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials.

Kitchens JW, Do DV, Boyer DS, Thompson D, Gibson A, Saroj N, Vitti R, Berliner AJ, Kaiser PK.

Ophthalmology. 2016 Jul;123(7):1511-20. doi: 10.1016/j.ophtha.2016.02.046. Epub 2016 Apr 12. Review.

PMID:
27084563
32.

Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye.

Abdelfattah NS, Zhang H, Boyer DS, Rosenfeld PJ, Feuer WJ, Gregori G, Sadda SR.

Invest Ophthalmol Vis Sci. 2016 Apr;57(4):1839-46. doi: 10.1167/iovs.15-18572.

PMID:
27082298
33.

Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).

Bhisitkul RB, Desai SJ, Boyer DS, Sadda SR, Zhang K.

Ophthalmology. 2016 Jun;123(6):1269-77. doi: 10.1016/j.ophtha.2016.01.033. Epub 2016 Mar 18.

PMID:
26996339
34.

Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.

Do DV, Nguyen QD, Vitti R, Berliner AJ, Gibson A, Saroj N, Soo Y, Boyer DS.

Ophthalmology. 2016 Apr;123(4):850-7. doi: 10.1016/j.ophtha.2015.11.008. Epub 2016 Jan 28.

PMID:
26832658
35.

Reply.

Bhisitkul RB, Mendes TS, Rofagha S, Enanoria W, Boyer DS, Sadda SR, Zhang K.

Am J Ophthalmol. 2016 Feb;162:200-1. doi: 10.1016/j.ajo.2015.11.001. Epub 2015 Nov 25. No abstract available.

PMID:
26621610
36.

Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.

Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA.

Ophthalmology. 2016 Feb;123(2):330-6. doi: 10.1016/j.ophtha.2015.09.035. Epub 2015 Oct 30.

PMID:
26522708
37.

Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.

Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack JS, Regillo CD, Rosenfeld PJ, Schachat AP, Wells JA 3rd; American Society of Retina Specialists Anti-VEGF for Diabetic Macular Edema Comparative Effectiveness Panel.

JAMA Ophthalmol. 2016 Jan;134(1):95-9. doi: 10.1001/jamaophthalmol.2015.4110.

PMID:
26512939
38.

Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials.

Boyer DS, Nguyen QD, Brown DM, Basu K, Ehrlich JS; RIDE and RISE Research Group.

Ophthalmology. 2015 Dec;122(12):2504-13.e1. doi: 10.1016/j.ophtha.2015.08.006. Epub 2015 Oct 9.

39.

Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.

Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Korobelnik JF.

Ophthalmology. 2015 Oct;122(10):2044-52. doi: 10.1016/j.ophtha.2015.06.017. Epub 2015 Jul 18.

PMID:
26198808
40.

Clinical Course of Vitreomacular Traction Managed Initially by Observation.

Tzu JH, John VJ, Flynn HW Jr, Smiddy WE, Jackson JR, Isernhagen BA, Carver A, Leonard R, Tabandeh H, Boyer DS, Berrocal MH, Suzuki M, Freund KB, Gross JG.

Ophthalmic Surg Lasers Imaging Retina. 2015 May;46(5):571-6. doi: 10.3928/23258160-20150521-09.

PMID:
26057761
41.

Mitochondrial DNA variants can mediate methylation status of inflammation, angiogenesis and signaling genes.

Atilano SR, Malik D, Chwa M, Cáceres-Del-Carpio J, Nesburn AB, Boyer DS, Kuppermann BD, Jazwinski SM, Miceli MV, Wallace DC, Udar N, Kenney MC.

Hum Mol Genet. 2015 Aug 15;24(16):4491-503. doi: 10.1093/hmg/ddv173. Epub 2015 May 10.

42.

PROSPECTIVE EVALUATION OF VISUAL ACUITY AGREEMENT BETWEEN STANDARD EARLY TREATMENT DIABETIC RETINOPATHY STUDY CHART AND A HANDHELD EQUIVALENT IN EYES WITH RETINAL PATHOLOGY.

Rahimy E, Reddy S, DeCroos FC, Khan MA, Boyer DS, Gupta OP, Regillo CD, Haller JA.

Retina. 2015 Aug;35(8):1680-7. doi: 10.1097/IAE.0000000000000518.

PMID:
25719987
43.

Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study.

Bhisitkul RB, Mendes TS, Rofagha S, Enanoria W, Boyer DS, Sadda SR, Zhang K.

Am J Ophthalmol. 2015 May;159(5):915-24.e2. doi: 10.1016/j.ajo.2015.01.032. Epub 2015 Jan 30.

PMID:
25640411
44.

Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.

Gonzalez VH, Boyer DS, Schmidt-Erfurth U, Heier JS, Gordon C, Benz MS, Marcus DM, Sabates NR, Vitti R, Kazmi H, Berliner AJ, Soo Y, Zhu X, Moini H, Zeitz O, Sandbrink R, Do DV.

Retina. 2015 Apr;35(4):687-94. doi: 10.1097/IAE.0000000000000430.

PMID:
25621943
45.

Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2.

Campochiaro PA, Sophie R, Tolentino M, Miller DM, Browning D, Boyer DS, Heier JS, Gambino L, Withers B, Brigell M, Peters K.

Ophthalmology. 2015 Mar;122(3):545-54. doi: 10.1016/j.ophtha.2014.09.023. Epub 2014 Nov 12.

PMID:
25439435
46.
47.

Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.

Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Haller JA.

Ophthalmology. 2015 Mar;122(3):538-44. doi: 10.1016/j.ophtha.2014.08.031. Epub 2014 Oct 12.

PMID:
25315663
48.

Comparison of the tissue penetration and glide force of 22-gauge thin-wall needles for intravitreal implant administration.

Bakri SJ, Boyer DS, Albini TA, Holekamp NM, Ferrone PJ, Bhagat R, Novakovic Z.

Ophthalmic Surg Lasers Imaging Retina. 2014 Sep-Oct;45(5):430-5.

PMID:
25230401
49.

Intravitreal aflibercept for diabetic macular edema.

Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM.

Ophthalmology. 2014 Nov;121(11):2247-54. doi: 10.1016/j.ophtha.2014.05.006. Epub 2014 Jul 8.

PMID:
25012934
50.

Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study.

Boyer DS, Goldbaum M, Leys AM, Starita C; V.I.S.I.O.N. Study Group.

Br J Ophthalmol. 2014 Nov;98(11):1543-6. doi: 10.1136/bjophthalmol-2013-304075. Epub 2014 Jul 4.

PMID:
24997182

Supplemental Content

Loading ...
Support Center